<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877486</url>
  </required_header>
  <id_info>
    <org_study_id>UR Cryo PVI</org_study_id>
    <nct_id>NCT01877486</nct_id>
  </id_info>
  <brief_title>PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide</brief_title>
  <acronym>ABLATE</acronym>
  <official_title>Pulmonary Vein Isolation Using Cryoablation Alone in Paroxysmal Atrial Fibrillation Patients Converted From Persistent Atrial Fibrillation With Dofetilide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of cryoablation alone in patients with paroxysmal atrial&#xD;
      fibrillation who have been pretreated with dofetilide and converted from persistent atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary vein isolation is now considered a cornerstone of all atrial fibrillation (AF)&#xD;
      ablation procedures. In patients with paroxysmal AF, pulmonary vein isolation alone is&#xD;
      usually sufficient. The cryoballoon is now FDA approved to achieve PVI in patients with&#xD;
      paroxysmal AF.&#xD;
&#xD;
      Although no ablation system is yet approved in patients with persistent AF, these patients&#xD;
      are increasingly undergoing ablation. Many investigators feel that these patients have more&#xD;
      atrial disease and thus PVI alone is insufficient in these patients. As a result, it is&#xD;
      common for these patients to undergo additional ablation, which is often quite extensive and&#xD;
      exposes patients to proarrhythmia. Commonly utilized strategies include linear lesions (left&#xD;
      atrial roof; mitral isthmus line), ablation of complex fractionated atrial electrograms&#xD;
      (CFAEs), left atrial appendage isolation and/or even right atrial ablation. For years, the&#xD;
      investigators have been concerned about the adverse effects of this additional ablation. The&#xD;
      investigators postulated that the &quot;answer&quot; is not more ablation but trying to &quot;reverse&#xD;
      remodel&quot; patients with persistent AF back to a paroxysmal form, whereby PVI alone would again&#xD;
      be justified and sufficient. The efficacy of such a strategy has previously been&#xD;
      demonstrated.&#xD;
&#xD;
      In brief, the investigators start patients with persistent AF on dofetilide 3 months prior to&#xD;
      scheduled ablation. In 96% of patients, AF either suppresses completely or is transformed&#xD;
      into a paroxysmal pattern. The net effect is &quot;reverse remodeling&quot; of the left atria. The&#xD;
      investigators have confirmed this by using a reduction in P wave duration as a surrogate of&#xD;
      remodeling. At the ablation procedure, the investigators perform PVI alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding not available&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation/flutter</measure>
    <time_frame>One year</time_frame>
    <description>As assessed by one week Holters and symptoms</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <description>After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Pulmonary vein isolation following dofetilide</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for catheter ablation of AF&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 80 years&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
          -  Paroxysmal AF, defined as recurrent AF ( ≥ 2 episodes in 1 month) that terminates&#xD;
             within 7 days as assessed by ECG recordings&#xD;
&#xD;
          -  Prior persistent AF, defined as sustained beyond seven days and up to one year,&#xD;
             successfully converted to paroxysmal AF by dofetilide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ablation for AF&#xD;
&#xD;
          -  Left atrial size larger than 60mm (parasternal view on transthoracic echocardiogram)&#xD;
&#xD;
          -  Patients who have AF episodes triggered by another uniform arrhythmia (e.g. atrial&#xD;
             flutter or atrial tachycardia)&#xD;
&#xD;
          -  Presence of severe valvular disease with the need for surgical correction&#xD;
&#xD;
          -  AF deemed secondary to a transient or correctable abnormality including electrolyte&#xD;
             imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy&#xD;
&#xD;
          -  Pregnant women or women of child bearing potential and not on reliable methods of&#xD;
             birth control&#xD;
&#xD;
          -  Second or third degree AV block, sinus pause &gt; 3 seconds, resting heart rate&lt; 30 bpm&#xD;
             without permanent pacemaker&#xD;
&#xD;
          -  History of drug-induced Torsades de Pointes or congenital long QT syndrome&#xD;
&#xD;
          -  Uninterrupted AF for more than 12 months prior to randomization unless sinus rhythm&#xD;
             maintained for ≥ 24 hours after cardioversion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Steinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2013</study_first_posted>
  <last_update_submitted>October 2, 2016</last_update_submitted>
  <last_update_submitted_qc>October 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jonathan S. Steinberg</investigator_full_name>
    <investigator_title>Adjunct Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cryoballoon ablation</keyword>
  <keyword>persistent AF</keyword>
  <keyword>paroxysmal AF</keyword>
  <keyword>dofetilide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

